Metagard

General characteristics. Structure:

Active agent: trimetazidina dihydrochloride of 20 mg.

Pharmacological properties:

The means normalizing power metabolism of the cells which underwent a hypoxia or ischemia. Prevents decrease in intracellular content of ATP, provides normal functioning of membrane ion channels, transmembrane transfer of potassium ions and sodium and preservation of a cellular homeostasis.
Trimetazidin slows down oxidation of fatty acids at the expense of the selection inhibition long-chain 3-ketoatsetil-KOA thiomanholes that leads to increase in oxidation of glucose and to recovery of interface between glycolysis and oxidizing decarboxylation and as it was shown, provides protection of a myocardium against ischemia. Switching of oxidation of fatty acids to oxidation of glucose is the cornerstone of anti-anginal action of a trimetazidin.
In pilot studies on animals it is shown what триметазидин supports power metabolism of heart and neurosensory bodies during the periods of episodes of ischemia; reduces the size of intracellular acidosis and extent of changes in the transmembrane ion flux arising at ischemia; lowers the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfusion tissues of heart, reduces the amount of injury of a myocardium; at the same time does not exert impact on a hemodynamics.

Pharmacokinetics. Trimetazidin is quickly and almost completely absorbed mucous intestines. Bioavailability makes 90%. Cmax is reached during 2 h and makes (after single oral administration of 20 mg of a trimetazidin) about 55 ng/ml. Vd – 4.8 l/kg. Easily passes through gistogematichesky barriers. Linkng with proteins of plasma makes 16%.
T1/2 is 4.5-5 h. It is removed by kidneys (about 60% - in not changed look).

Indications to use:

Long therapy of an ischemic heart disease: prevention of attacks of stenocardia (monotherapy or as a part of a combination therapy); treatment of cochleovestibular disturbances of the ischemic nature (including dizziness, sonitus, hearing disorder); chorioretinal vascular disorders with an ischemic component.

Route of administration and doses:

Accept inside in a dose 40-60 mg/days, frequency rate of reception of 2-3 times/days. Duration of therapy is established individually, depending on a clinical situation.

Features of use:

Trimetazidin does not influence ability to driving of the car and performance of work, the psychomotor reactions demanding high speed.

Side effects:

Perhaps: allergic reactions (including skin rash, itch).
Seldom: nausea, vomiting, gastralgia.

Interaction with other medicines:

There are no data.

Contraindications:

Pregnancy, the period of a lactation (breastfeeding), hypersensitivity to a trimetazidin.

Use at pregnancy and feeding by a breast
Trimetazidin is contraindicated to use at pregnancy and in the period of a lactation (breastfeeding).

Overdose:

It is not described.

Storage conditions:

List B. In the dry place protected from light, at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets, film coated, 20 mg. On 10 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. 2, 3 or 6 blister strip packagings together with the application instruction place in a pack.